• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

April 8, 2019
Company Drug/Device Medical Condition Status
Tizona Therapeutics, Inc. TTX-030 cancer Phase I/Ib trial initiated
Amylyx Pharmaceuticals, Inc. AMX0035 Alzheimer’s Disease Phase II trial initiated enrolling 100 subjects
Odonate Therapeutics, Inc. tesetaxel locally advanced or metastatic breast cancer (MBC) Phase II trial initiated
Poxel SA PXL770 non-alcoholic steatohepatitis (NASH) Phase IIa trial initiated enrolling 100 subjects with nonalcoholic fatty liver disease (NAFLD) who likely have NASH at sites in the U.S.
Biohaven Pharmaceutical Holding Company, Ltd. BHV-3500 migraine Phase II/III trial initiated
Hutchison China MediTech Limited surufatinib (HMPL-012 or sulfatinib) with capecitabine advanced biliary tract cancer (BTC) Phase IIb/III trial initiated
PellePharm, Inc. Patidegib Topical Gel, 2% Gorlin Syndrome Phase III trial initiated enrolling 150 subjects
Aldeyra Therapeutics, Inc. topical ocular reproxalap dry eye disease Phase III trial initiated enrolling 400 subjects with moderate-to-severe dry eye disease
ACell, Inc. Gentrix Surgical Matrix gastroenterological or plastic and reconstructive surgery 510(k) clearance granted by the FDA
ACell, Inc. Gentrix Surgical Matrix Thin urological, gastroenterological or plastic and reconstructive surgery 510(k) clearance granted by the FDA
ACell, Inc. Gentrix Surgical Matrix Plus gastroenterological or plastic and reconstructive surgery 510(k) clearance granted by the FDA
AstraZeneca and Merck selumetinib NF1 plexiform neurofibromas Breakthrough Therapy designation granted by the FDA
CSA Medical, Inc. RejuvenAir System moderate to severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB) Breakthrough Device designation granted by the FDA
Fera Pharmaceuticals Avaclyr (acyclovir ophthalmic ointment) herpetic keratitis NDA approval granted by the FDA
Intellirod Spine LOADPRO kyphotic correction surgery De Novo approval granted by the FDA
Immunocore Limited tebentafusp (IMCgp100) metastatic uveal melanoma (mUM) Fast Track approval granted by the FDA
Clarus Therapeutics Jatenzo (testosterone undecanoate) hypogonadism Approval granted by the FDA
EMD Serono Mavenclad (cladribine) relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS) Approval granted by the FDA

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing